Reference Detail

Ref Type

Journal Article

PMID

(34117033)

Authors

Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, Weinberg BA, VanderWalde AM, Tesfaye A, Raymond VM, Miron B, Tarcic G, Zelichov O, Broaddus RR, Ng PKS, Jeong KJ, Tsang YH, Mills GB, Overman MJ, Grothey A, Marshall JL, Kopetz S

Title

Clinical and functional characterization of atypical KRAS/NRAS mutations in metastatic colorectal cancer.

Journal	Vol	Issue	Date	Pages	Journal Short Title
Clinical cancer research : an official journal of the American Association for Cancer Research			2021 Jun 11	4587-4598	Clin Cancer Res

URL

Abstract Text

Mutations in KRAS/NRAS (RAS) predict lack of anti-EGFR efficacy in metastatic colorectal cancer (mCRC). However, it is unclear if all RAS mutations have similar impact and atypical mutations beyond those in standard guidelines exist.We reviewed 7 tissue and 1 cfDNA cohorts of 9485 patients to characterize atypical RAS variants. Using an in-vitro cell-based assay (FACT), Ba/F3 transformation and in-vivo xenograft models of transduced isogenic clones, we assessed signaling changes across mutations.KRAS exon 2, extended RAS, and atypical RAS mutations were noted in 37.8%, 9.5%, and 1.2% of patients, respectively. Among atypical variants, KRAS L19F, Q22K and D33E occurred at prevalence {greater than or equal to}0.1%, while no NRAS codon 117/146 and only one NRAS codon 59 mutation was noted. Atypical RAS mutations had worse overall survival than RAS/BRAF wild-type mCRC (HR 2.90, 95% CI 1.24-6.80, P=0.014). We functionally characterized 114 variants with the FACT assay. All KRAS exon 2 and extended RAS mutations appeared activating. Of 57 atypical RAS variants characterized, 18 (31.6%) had signaling below wild-type, 23 (40.4%) had signaling between wild-type and activating control, and 16 (28.1%) were hyperactive beyond the activating control. Ba/F3 transformation (17/18 variants) and xenograft model (7/8 variants) validation was highly concordant with FACT results and activating atypical variants were those that occurred at highest prevalence in clinical cohorts.We provide best available evidence to guide treatment when atypical RAS variants are identified. KRAS L19F, Q22K, D33E and T50I are more prevalent than many guideline included RAS variants and functionally relevant.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description
NRAS	A18T	missense	no effect - predicted	NRAS A18T lies within a GTP-binding region of the Nras protein (UniProt.org). A18T results in MAPK/ERK pathway activation similar to wild-type Nras in an in vitro assay (PMID: 34117033), and therefore, is predicted to have no effect on Nras protein function.
NRAS	G12R	missense	loss of function	NRAS G12R is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). G12R results in increased MAPK/ERK pathway activation in an in vitro assay, is transforming in culture (PMID: 34117033), and is predicted to lead to a loss of Nras protein function based on the effects of HRAS G12R (PMID: 3042780, PMID: 6092966).
NRAS	G13R	missense	loss of function - predicted	NRAS G13R is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). G13R results in increased MAPK/ERK pathway activation in an in vitro assay, is transforming in culture (PMID: 34117033), and can be predicted to lead to a loss of Nras protein function based on the effects of other NRAS G13 mutations.
NRAS	K135N	missense	no effect	NRAS K135N lies within the G domain of the Nras protein (PMID: 17384584). K135N results in similar cell proliferation and viability levels to wild-type Nras in cultured cells (PMID: 29533785, PMID: 34117033) and shows similar MAPK/ERK pathway activation to wild-type Nras in an in vitro assay (PMID: 34117033).
NRAS	Q61K	missense	loss of function - predicted	NRAS Q61K is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). Q61K results in activation of downstream pathway signaling, increased survival, and transformation of cultured cells (PMID: 22718121, PMID: 34117033, PMID: 33431353), and is predicted to lead to a loss of Nras protein function based on the effects of HRAS Q61K (PMID: 3510078).
NRAS	Q61R	missense	loss of function - predicted	NRAS Q61R is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). Q61R results in increased GTP-bound Nras, which leads to activation of Mapk signaling and cell transformation in culture (PMID: 16818621, PMID: 34117033), and is predicted to lead to a loss of GTPase activity based on the effect of HRAS Q61R (PMID: 3510078).
NRAS	R164C	missense	no effect - predicted	NRAS R164C lies within the G domain of the Nras protein (PMID: 17384584). R164C results in MAPK/ERK pathway activation similar to wild-type Nras in an in vitro assay (PMID: 34117033), and therefore, is predicted to have no effect on Nras protein function.

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
NRAS K135N	colorectal cancer	predicted - sensitive	Cetuximab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a cell line xenograft model of colorectal cancer expressing NRAS K135N demonstrated similar sensitivity to Erbitux (cetuximab) treatment compared to a NRAS wild-type model (PMID: 34117033).	34117033